Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II signal finding study of AEVI-002 in severe pediatric patients with Crohn's Disease who previously failed treatment with an Anti-TNFa inhibitor

Trial Profile

A Phase I/II signal finding study of AEVI-002 in severe pediatric patients with Crohn's Disease who previously failed treatment with an Anti-TNFa inhibitor

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AEVI 002 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2018 According to an Aevi Genomic Medicine media release, the Company has not yet enrolled any patients into this trial and expects to enrol a small number of patients by the end of the first quarter of 2019. Initial data is expected by mid-year 2019.
    • 13 Mar 2018 According to an Aevi Genomic Medicine media release, the company is initiating three additional sites in an effort to enhance enrollment and data expected by year-end 2018.
    • 02 Nov 2017 According to an Aevi Genomic Medicine media release, initial data is anticipated by mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top